TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in Morrisville, North Carolina and currently employs 399 full-time employees. The firm is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. The company also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.
How did TGTX's recent EPS compare to expectations?
The most recent EPS for TG Therapeutics Inc is $0.14, not beating expectations of $0.35.
How did TG Therapeutics Inc TGTX's revenue perform in the last quarter?
TG Therapeutics Inc revenue for the last quarter is $0.14
What is the revenue estimate for TG Therapeutics Inc?
According to 10 of Wall street analyst, the revenue estimate of TG Therapeutics Inc range from $219.98M to $190.15M
What's the earning quality score for TG Therapeutics Inc?
TG Therapeutics Inc has a earning quality score of A-/59.450245. The score is based on a four dimension of Profitability, Growth, Cash generation & Capital Allocation, and Leverage.
When does TG Therapeutics Inc report earnings?
TG Therapeutics Inc next earnings report is expected in 2026-05-27
What are TG Therapeutics Inc's expected earnings?
TG Therapeutics Inc expected earnings is $196.05M, according to wall-street analysts.
Did TG Therapeutics Inc beat earnings expectations?
TG Therapeutics Inc recent earnings of $192.57M does not beat expectations.